Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

The Shift Toward a Functional Cure in Chronic Hepatitis B

For decades, the management of chronic hepatitis B (CHB) has been defined by a frustrating reality: the goal was suppression, not a cure. Most patients relied on nucleos(t)ide analogues, medications that effectively retain the virus in check but often require lifelong administration.

The industry is now pivoting toward a more ambitious objective known as the “functional cure.” Unlike traditional suppression, a functional cure occurs when the hepatitis B surface antigen (HBsAg) and HBV DNA grow undetectable in the blood for at least 24 weeks after all treatment has stopped. This indicates that the patient’s own immune system has regained control over the infection.

This shift is not just about stopping medication; it is about fundamentally altering the trajectory of the disease. Achieving a functional cure is linked to a significant reduction in the risk of long-term liver complications, most notably liver cancer.

How Bepirovirsen is Redefining Treatment Potential

The emergence of bepirovirsen, an investigational antisense oligonucleotide (ASO), represents a potential first-in-class approach to achieving these functional cures. Unlike traditional antivirals, bepirovirsen employs a triple-action mechanism to attack the virus from multiple angles.

The Triple-Action Mechanism

Bepirovirsen is designed to orchestrate the destruction of the genetic components of the hepatitis B virus. Specifically, it targets mRNA and pregenomic RNA, which are essential for the virus to replicate and maintain its presence in the body.

By inhibiting the replication of the viral genome and suppressing HBsAg levels in the blood, the therapy aims to “unmask” the virus, stimulating the patient’s immune system to mount a durable and sustained response.

Recent Phase III B-Well 1 and B-Well 2 trials, conducted across 29 countries, have demonstrated that bepirovirsen, when used alongside the standard of care, produces statistically significant and clinically meaningful functional cure rates compared to using the standard of care alone.

The Global Burden and the Urgency for Innovation

The scale of the CHB challenge is immense. More than 250 million people worldwide live with the infection, and in the United States alone, an estimated 1.7 million people are affected. The human cost is equally staggering, with the disease causing approximately 1.1 million deaths globally every year.

Because chronic hepatitis B is a leading cause of liver cancer, the transition from “lifelong management” to “functional cure” is a public health imperative. The FDA’s decision to grant bepirovirsen both Fast Track and Breakthrough Therapy Designations underscores the potential for this medicine to offer a substantial improvement over available therapies.

Future Trends: Combination and Sequential Therapies

Looking ahead, the trend in HBV research is moving toward “backbone therapy.” Bepirovirsen is being evaluated not just as a standalone addition, but as a foundation for future sequential treatment strategies.

The goal is to expand the possibility of a functional cure to broader, more diverse patient populations. By combining ASOs with other emerging modalities, researchers hope to create a roadmap that clears the virus entirely, regardless of the patient’s initial viral load or immune status.

With global regulatory filings underway and a PDUFA goal date of October 26, 2026, the medical community is closely watching to see if this marks the beginning of the finish for lifelong HBV therapy.

Frequently Asked Questions